Search
QR-334
go.drugbank.com/drugs/DB05473ExperimentalQR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. … No pharmaceutical interventions currently exist to treat sialorrhea.
Cloxazolam
go.drugbank.com/drugs/DB01553ExperimentalThe usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety.
Chlormezanone
go.drugbank.com/drugs/DB01178ApprovedWithdrawnIt has been suggested for use in the treatment of muscle spasm.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological … hallmarks that are common to amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD).
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalThe compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056]. … These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19.
Categories: Experimental Unapproved Treatments for COVID-19Linifanib
go.drugbank.com/drugs/DB06080InvestigationalLinifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels
EMZ702
go.drugbank.com/drugs/DB05021InvestigationalEMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … compared to interferon and ribavirin alone.
Succinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary